Humira Pen 40 Mg/0.4 Ml Starter Pack Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Humira Pen Starter Pack Availability in 2026

If your patients are reporting difficulty filling prescriptions for the Humira Pen 40 Mg/0.4 Ml Starter Pack, they're not imagining things. While brand-name Humira (Adalimumab) is not in formal shortage, the U.S. market has undergone a fundamental transformation since the first biosimilars launched in January 2023.

This briefing covers what you need to know as a prescriber: the current availability picture, formulary implications, cost considerations, and tools to help your patients access treatment without interruption.

Timeline: How We Got Here

Understanding the current landscape requires context:

• 2002: Humira (Adalimumab) receives initial FDA approval for rheumatoid arthritis.
• 2016–2020: Multiple Adalimumab biosimilars receive FDA approval, but legal settlements with AbbVie delay U.S. market entry.
• January 2023: First biosimilars (Amjevita by Amgen, Hadlima by Organon/Samsung Bioepis) launch in the U.S.
• 2023–2024: Eight additional biosimilars enter the market, including Cyltezo, Hyrimoz, Hulio, Yuflyma, Idacio, Yusimry, and Simlandi.
• 2024–2025: Multiple biosimilars receive interchangeability designations. PBMs begin preferring biosimilars on national formularies.
• 2026: More than 10 Adalimumab biosimilars are available. Hyrimoz leads with approximately 47% of biosimilar switches, followed by Simlandi (24%) and Hadlima (13%). Brand-name Humira market share continues to decline.

Prescribing Implications

Formulary Shifts Are Driving Access Challenges

Major PBMs have restructured their formularies to favor biosimilars:

• Express Scripts includes Cyltezo and Sandoz products (branded Hyrimoz and unbranded Adalimumab-adaz) as preferred products on its National Preferred Formulary alongside Humira.
• CVS Caremark and OptumRx have implemented similar biosimilar-preferring strategies.
• Many plans now require prior authorization with medical necessity documentation for brand-name Humira when a biosimilar alternative is available.

For patients initiating therapy, writing for a biosimilar from the start can eliminate prior authorization delays and improve time-to-treatment.

Interchangeability Considerations

As of 2026, the following Adalimumab biosimilars carry FDA interchangeability designations: Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, and Simlandi. In most states, pharmacists can substitute these for brand-name Humira without contacting the prescriber, unless "dispense as written" is indicated.

Clinical data supports that switching between the reference product and an interchangeable biosimilar does not result in clinically meaningful differences in efficacy, safety, or immunogenicity.

Starter Pack Availability

The Humira Pen Starter Pack (containing multiple pens for induction dosing) is a specialty configuration. As pharmacy inventory shifts toward biosimilars, this specific packaging has become harder to source. When initiating patients on Adalimumab therapy, consider whether a biosimilar with equivalent induction dosing is available in a comparable starter configuration.

Current Availability Picture

Brand-name Humira is not on the FDA drug shortage list. However, practical availability varies:

• Specialty pharmacies (Accredo, CVS Specialty, AllianceRx Walgreens Prime) generally maintain access to brand-name Humira when prior authorization is secured.
• Retail pharmacies have significantly reduced brand-name Humira inventory. Starter packs are particularly scarce at retail locations.
• Some biosimilar formulations have experienced intermittent supply disruptions as manufacturers scale production.

Providers can use Medfinder for Providers to check real-time pharmacy availability and help patients identify pharmacies with their prescribed formulation in stock.

Cost and Access Considerations

Cost remains a significant factor in treatment decisions:

ProductList Price (2-pen carton)vs. HumiraHumira (brand)~$6,900ReferenceHyrimoz (branded)~$6,576-5%Hyrimoz (unbranded)~$1,315-81%Hadlima~$1,038-85%Amjevita~$3,100-55%

For commercially insured patients, AbbVie's HUMIRA Complete Savings Card can reduce out-of-pocket costs to as little as $5/month. However, this is not available to government-insured patients.

Medicare Part D patients benefit from the Inflation Reduction Act's $2,100 annual out-of-pocket cap in 2026.

For uninsured patients, the myAbbVie Assist patient assistance program provides free medication to those who qualify. Biosimilar manufacturers also offer their own patient support programs.

Tools and Resources for Providers

• Medfinder for Providers: Real-time pharmacy availability search. Share with patients or use in your workflow to identify stocking pharmacies.
• HUMIRA Complete (1-800-4HUMIRA): AbbVie's support program assists with prior authorization, pharmacy coordination, and patient financial support.
• Biosimilar manufacturer programs: Sandoz (Hyrimoz), Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), and Organon (Hadlima) all offer provider and patient support resources.
• ASHP Drug Shortages Resource Center: Monitor current shortages at ashp.org.

Looking Ahead

The Adalimumab biosimilar market is maturing rapidly. Key trends to watch in 2026:

• Continued formulary consolidation: PBMs are likely to narrow preferred biosimilar lists, potentially improving supply chain predictability.
• Price competition: As more interchangeable biosimilars compete, downward price pressure should continue benefiting patients.
• Non-medical switching: Payers may increasingly require switches from brand-name Humira to biosimilars at renewal. Prepare patients for this possibility and document clinical rationale if brand-name is medically necessary.
• New delivery technologies: Some manufacturers are exploring alternative delivery devices that may improve patient experience.

Final Thoughts

The Humira Pen 40 Mg/0.4 Ml Starter Pack availability challenge in 2026 reflects a market in transition, not a manufacturing shortage. As prescribers, you can help patients navigate this by staying current on formulary preferences, considering biosimilar alternatives when initiating therapy, and leveraging tools like Medfinder for Providers.

For a practical guide on helping patients locate their medication, see How to Help Your Patients Find Humira in Stock: A Provider's Guide. For patient-facing savings information to share, see How to Help Patients Save Money on Humira: A Provider's Guide.